Dr. David Jablons | San Francisco, California

Dr. David Jablons is a Mesothelioma Cancer Doctor at University of California, San Francisco Medical Center, located in San Francisco, California.

Mesothelioma Doctor Information

Dr. David Jablons - San Francisco, California
Dr. Jablons is the Program Leader of the Thoracic Oncology Program at the University of California, San Francisco (UCSF) and a Program Member of the UCSF Comprehensive Cancer Center. Current research initiatives include the molecular biology of non-small cell lung cancer and mesothelioma with emphasis on gene discovery through differential display and subtraction hybridization techniques in primary tumors, metastases, and cell lines.

UCSF Comprehensive Cancer Center
Box 0128, UCSF
San Francisco, California 94143-0128
Phone: (800) 888-8664 or (415) 885-7777
Website: http://cc.ucsf.edu/index.html

Education:
Yale University, New Haven, CT, B.A., 1979, American Lit.
Albany Medical College, Albany, NY, M.D., 1984, Medicine

Professional Experience:
7/1/84-6/30/85-Intern, Naval Medical Center, Oakland, CA

7/1/85-6/30/86-Resident in General Surgery, Tufts-New England Medical Center, Boston, MA

7/1/86-6/30/89-Clinical Associate, Surgery Branch, NCI, NIH, Bethesda, MD

7/1/89-6/30/91-Senior and Chief Resident in General Surgery, Tufts-New England Medical Center, Boston, MA

7/1/91-6/30/93-Resident in Cardiothoracic Surgery, Cornell University, New York Hospital, New York, New York

7/1/93-8/30/95-Head, Division of Thoracic Surgery, Naval Medical Center, Oakland, CA

11/1/94-8/30/95-Assistant Clinical Professor of Surgery, University of California, San Francisco-Mount Zion Medical Center

8/1/95-2/01-Assistant Professor of Surgery, University of California, San Francisco-Mount Zion Medical Center

2/1/97-present-Chief, Section of General Thoracic Surgery, University of California, San Francisco-Mount Zion Medical Center

7/1/98-present-Program Leader, Thoracic Oncology-UCSF Comprehensive Cancer Center

7/01-present-Associate Professor of Surgery, University of California, San Francisco-Mount Zion Medical Center

10/1/01-present-ADA endowed chair in Thoracic Oncology

Honors and Awards:
Mosby Freshman Prize for Focal Problems in Medicine, 1981 American Cancer Society Glen Leak Memorial Fellowship, 1982 C.R. Bard Senior Prize, 1984

Jablons D.M., Lotze D.T. Derivation of cells with lytic activity against fresh and cultured tumors from human bone marrow. J Surg Res, 1988, 44:404.

Jablons D.M., Mule J.J., McIntosh J.K., Sehgal P.B., May L.T., Huang C.M., Rosenberg S.A., Lotze M.T. Interleukin-6/interferon-beta-2 as a circulating hormone: induction after cytokine administration in humans. J Immunol, 1989, 142:1542.

McIntosh J.K., Jablons D.M., Mule J.J., Nordan R., Rudikoff S., Lotze M.T., Rosenberg S.A. The induction of interleukin-6/interferon beta-2 by recombinant cytokine administration and detection of circulating IL-6 in tumor bearing animals. J Immunol, 1989, 143:162.

McIntosh J.K, Mule J.J., Jablons D.M., Nordan R., Rudikoff S., Lotze M., Rosenberg S.A. The kinetics of interleukin-6(IL-6) induction by the systemic administration of rhTNF-alpha in mice. Proc NY Acad Sci, 1989.

Jablons D.M., Bolton E., Mertins S., Rubin M., Pizzo P., Rosenberg S.A., Lotze M.T. Interleukin-2 (IL-2) based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis. J Immunol, 1990, 144:3630.

Jablons D.M., Donahue R., Kawakami Y., Young J.D., Lotze M.T. Interleukin-3 (IL-3) induces proliferation but not lymphokine-activated killer (LAK) from human and murine mononuclear cells. Eur Cytokine Network, 1990, 2:56.

Mule J.J., McIntosh J.K., Jablons D.M., Rosenberg S.A. Antitumor activity of recombinant interleukin-6 in mice. J Exp Med, 1990, 171:629.

Greenberg A., Nordan R.P., McIntosh J.K., Calvo J.C., Scow R., Jablons D.M. Interleukin-6 reduces lipoprotein activity in adipose tissue of mice in vivo and in 3T3;L1 lipocytes: a possible role for interleukin-6 in cancer cachexia. Cancer Res, 1992, 52:4113.

Rajasinghe H., McElhinney D.B., Chen J.C., Merrick S.H., Keith F.M., Jablons D.M., Cameron R.B. Predictors of Post-Pneumonectomy Pulmonary Edema: Significance of Cardiac Function. Chest, 1996, 80S.

Jablons D.M., Cameron R.B., Xia W., Leland P., Varricchio F., Puri R. In vitro and in vivo expression of IL-4 receptors on human malignant mesothelioma: Implications for therapy. Proceedings of the American Association for Cancer Research, 1997, 38:631.

Key S., Cameron R.B., Jablons D.M. The Heimlich Device in Thoracic Surgery. Surgical Technology VI, 1997.

Jablons D.M., Roach III M., Jahan T., Cameron R.B. Resection and IORT Followed by Three-Dimensional Conformal Radiotherapy with or without Adjuvant Chemotherapy or Malignant Mesothelioma. Front Radiat Ther Oncol, 1997, vol 31.

Jablons D.M., Cameron R.B., Xia W, Varrichio F, Lelan P, Kreitman R, Pastan I, Puri R. Detection of IL-4 Receptors on Human Mesotheliomas and Demonstration of Specific Cytotoxicity by a Recombinant IL-4 Pseudomonas Exotoxin Against Mesothelioma Cell Lines. Chest, November 1997.

Khan J, Rahman S, Clary-Macy C, Anthony J, Keith F, Hall T, Jablons D.M. Strategies and Meta-analysis for Management of Bronchopleural Fistula. American College of Chest Physicians, December 1997.

Khan J, Varrichio F, Cameron R, Roach M, Jahan T, Puri R, Jablons D.M. Multi-modality Therapy for Malignant Mesothelioma and Detection of IL-4 Receptors on Human Mesotheliomas. American College of Chest Physicians, December 1997.

Khan J, Xia W, Varrichio F, Puri R, Jablons D.M. IL-4 Receptor Expression Marks Malignant Behavior of Human Pleura Tumors. Abstract-American College of Chest Physicians, May 1998.

Khan J, Rahman S, Clary-Macy C, Kerlin R, George T, Rosa G, Hall T, Jablons D.M. Giant Solitary Fibrous Tumor of the Pleura. Ann Thorac Surg 1998 May;65(5):1461-4.

Lim M, Martinez T, Jablons DM, Cameron RB, Basbaum C: The Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) mRNA is Strongly Expressed in Non-Small Cell Lung Carcinoma and Not Normal Lung. FEBs Letters, December 1998, 441(1): 88-92.

You L, McIntosh J, Jablons DM. Absence of Beta-Catenin Mutations in Malignant Mesotheliomas. American Association for Cancer Research Annual Meeting, April 1999.

Song JM, Treseler P, Baehner F, You L, Clary-Macy C, Jablons DM. Tumor Angiogenesis and Vascular Endothelial Growth Factor Expression in Malignant Mesothelioma. Abstract-American Association for Cancer Research Annual Meeting, April 1999.

You L, Kirn DH, McCormick F, Jablons DM. A Selectively-Replicating Adenovirus Therapy Works Synergistically with Chemotherapy in Lung Cancer. Abstract-Annual Meeting of the American Society of Clinical Oncology, May 1999.

Brevetti G, Clary-Macy C, Jablons DM: Pulmonary Placental Transmogrification: Diagnosis and Treatment. Journal of Thoracic and Cardiovascular Surgery, November 1999; 118(5):966-7.

You L, Yang C, Jablons DM. ONYX-015 Work Synergistically with Chemotherapy in Lung Cancer Cell Lines and Primary Cultures Freshly Made from Lung Cancer Patients. Cancer Research, 60(4):1009-13, February 2000.

Yang C, You L, Yeh C, Chang J, Chang F, McCormick F, Jablons DM. Cell Cycle Arrest and Induction of Apoptotic Death in Mesothelioma Cells by the Adenovirus-mediated p14ARF Expression. Journal of the National Cancer Institute, 19;92(8):636-41, April 2000.

Khan J, Hall T, Rahman S, Clary-Macy C, Harmon A, Jablons DM. Management Strategies for Bronchopleural Fistula. Asian Annals of Cardiovascular and Thoracic Surgery, Volume 8, Number 1, May 2000.

Schneider D, Clary-Macy C, Challa S, Sasse K, Merrick S, Hawkins R, Caputo G, Jablons DM. The Role of FDG Positron Emission Tomography in Evaluation of Patients with Malignant Mesothelioma for Multimodality Therapy. J ThoracCardiovasc Surg, July 2000; 120:128-33.

You L, Yang C. Zang K, Xie J, Treseler P, McCormick, Jablons DM. Profiling of Differentially Expressed Genes in Human Malignant Pleural Mesotheliomas. In press, Cancer Research, August 2000.

Brevetti G, Sasse K, Khan J, Wilson M, Clary-Macy C, Hall T, Jablons DM. Giant Tumors of the Chest: Preoperative Embolization and Resection. J Cardiovasc Surg (Torino), December 2000;41(6):945-52.

Moody TW, Walters J, Dudek J, Zakowicz H, Linnoila I, You L, Jablons DM, Paweletz C, Petricoin E. Seldi Analysis of Lung Cancer Biopsy Specimens. AACR 92nd Annual Meeting, New Orleans, March 2001.

Casibang M, Purdom S, Jakowlew S, Neckers L, Zia F, Ben-Av P, Hla T, You L, Jablons DM, Moody T. Prostaglandin E2 Increases Vascular Endothelial Cell Growth Factor mRNAS in Lung Cancer Cells. Lung Cancer, March 2001, 31(2-3):203-212.

McCowin M, Hall T, Babcock W, Solinger L, Hall K, Jablons DM. The Impact of Changes in Radiographic Abnormalities in Organ Donors on Successful Lung Donation. International Society for Heart and Lung Transplant Annual Meeting, April 2001.

Yang C, You L, Uematsu K, Yeh C, McCormick F, Jablons DM. P14ARF Modulates the Cytolytic Effect of ONYX-015 in Mesothelioma Cells with Wild-type p53. Cancer Research, August 2001, 61:5959-5963.

Jahan T, Glassberg A, Cornett P, Haas-Kogan D, Jablons DM. Everyone's Guide For Cancer Therapy: Small Cell Lung Cancer. 4th Edition, 2000.

Jahan T, Glassberg A, Cornett P, Haas-Kogan D, Anastassiou P, Jablons DM. Everyone's Guide For Cancer Therapy: Non-Small Cell Lung Cancer. 4th Edition, 2000.

Dollinger M, Rosenbaum E, Jahan T, Jablons DM. Everyone's Guide For Cancer Therapy: Mesothelioma. 4th Edition, 2000.

Dollinger M, Rosenbaum E, Jahan T, Jablons DM. Everyone's Guide For Cancer Therapy: Thymus. 4th Edition, 2000.

Clark O, Dollinger M, Jahan T, Jablons DM. Everyone's Guide For Cancer Therapy: Thyroid. 4th Edition, 2000.

Current research: http://cc.ucsf.edu/research/thoracic.html

Additional information about Dr. Jablons can be found at:
www.cc.ucsf.edu/people/jablons_david.html

If you or a loved one has been diagnosed with an illness related to asbestos such as mesothelioma, speaking with a mesothelioma lawyer can help you understand if you have legal options for compensation.

Mesothelioma Lawsuit Evaluation

9145

By submitting this form I agree to the Terms of Use

Find a Doctor

Finding a mesothelioma doctor who is familiar with the disease and its treatment will help to ensure that you receive the best medical care possible. Contact a local specialist today.

Find a Doctor

Clinical Trials

Though there is currently no cure for mesothelioma, various clinical trials are underway to test new drugs and treatments in the fight against this disease. Search active clinical trials.

Find a Clinical Trial

Exposure Sites

Asbestos, the only known cause of mesothelioma cancer, was used for decades in jobsites throughout the country. Review a list of known asbestos exposure locations in your area.

Search Exposure Sites